Abstract P56 Table 1

		Asthma (n = 146)	COPD (n = 85)
Exacerbations in previous 12 months	Oral antibiotics and/or oral steroids per patient	1.7 per patient (range: 0 -12)	3.0 per patient (range: 0 -15)
	Number of A&E attendances, n (mean/patient)	33 (0.23)	33 (0.39)
	Number of hospital admissions, n (mean/patient)	14 (0.10)	26 (0.31)
	Good technique	27.6% (40)	23.8% (20)
	Moderate technique	16.5% (24)	25.0% (21)
Inhaler technique (n)	Poor technique	55.9% (81)	51.2% (43)
	Pre review (range: 200–4000)	1669.9mcg	NA
Beclomethasone dipropionate equivalence (BDP)	Post review (range: 400–2000)	1044.1mcg	NA
	Current	24.7% (36)	36.5% (31)
	Quit rates (for ≥3months) post follow up	50.0% (18)	58.1% (18)
	Ex smoker	17.8% (26)	56.5% (48)
Smoking history (n)	Mean pack year history	30.1	57.1
	Maintenance ICS/LABA or ICS	7.9 (7.0)	8.4 (8.0)
	Long acting antimuscarinic	NA	9.8 (10.0)
Mean adherence to medicines in previous 12 months (median)	Reliever inhaler	9.3 (7.0)	14.3 (12.5)
Reliever Inhaler Use (times per day)		2.2	3.0
On correct therapy based on symptoms, diagnosis and disease severity (n)		24.0% (35)	35.3% (30)
	Step down	74.8% (83)	NA
	Stopping a part of treatment	25.2% (28)	67.3% (37)
If not on correct therapy, intervention made (n)	Querying the correct diagnosis	7.2% (8)	16.4% (9)
BTS/SIGN Step 4–5		74%	NA
FEV1% of predicted mean		NA	51.5%
	Baseline	353.3	NA
Peak Expiratory Flow Rate	Follow Up	375.5	NA
	Baseline	15.8	NA
ACT score mean	Follow Up	17.3	NA
	Baseline	NA	21.0
CAT score mean	Follow Up	NA	18.9
	Baseline	39.7% (58)	21.2% (18)
Night time wakening	Follow Up	17.6% (26)	20.0% (17)
	Baseline	2.2	3.0
Reliever inhaler use per day (mean)	Follow Up	1.3	1.9

out (62.4% follow up). 20.8% (n = 48) patients were followed up at the 6 or 12 month stage. Mean age was 53.0 and 67.6 years, with 34.2% and 56.5% males in the asthma and COPD groups respectively.

Table 1, below, shows a significant proportion of patients had uncontrolled disease. This was likely to be due to poor adherence to maintenance inhalers and poor inhaler technique in a large proportion of patients. Interventions were made in all patients, including reducing the beclomethasone dipropionate (BDP) equivalence in the asthma group by 625.8 mcg (37.5%).

Annual drug cost savings attributed to appropriate step down and cessation of therapy showed amounted to £51.8 K (asthma: £36.4 K; COPD: £15.4 K). Follow up exacerbation data is ongoing, with 48 patients (20.8%) having been seen at the 6 or 12 month stage, showing significant reductions from 1.7% to 0.04% and 3.0% to 0.14% in asthma and COPD respectively.

Conclusions Structured asthma and COPD reviews have shown that a significant proportion of patients have uncontrolled disease despite use of extensive and high dose pharmacological therapy. Structured reviews by the pharmacist resulted in significant interventions that improved ACT and CAT scores and reduced unwarranted healthcare utilisation. Furthermore, it showed that appropriate prescribing and disease management in line with national standards of care also resulted in significant drug cost savings.

P57 | **FACTORS INFLUENCING LENGTH OF HOSPITAL STAY IN ASTHMA EXACERBATIONS: RESULTS OF A SERVICE IMPROVEMENT PROJECT**

AJ Hanson, Y Vali, JRA Fisher-Black, G Woltmann, M Richardson, AJ Wardlaw, S Siddiqui. *University Hospitals of Leicester NHS Trust and NIHR Respiratory Biomedical Research Unit, Leicester, UK*

Background Asthma exacerbations pose a significant burden to the NHS, however the factors that underpin inpatient length of stay remain poorly understood. We undertook a service improvement project using hospital episode statistics to evaluate the demographics of the asthma hospital exacerbation population in Leicester hospitals and risk factors that influence length of stay.

Methods Hospital episode statistics were generated using an ACCESS database query set capturing a range of clinical meta data including length of stay, ICD-10 coding for two types of asthma admission (asthma and status asthmaticus), sex, age, ethnicity, financial year quarter of admission. In addition comorbidity was calculated by cross referencing spell diagnoses to the Charlson comorbidity index score. This database was subsequently linked to pathology data reporting blood eosinophils, neutrophils, CRP at admission and the highest ever historical blood eosinophil count. A backwards logistic regression model

was used to identify factors that increased length of stay beyond the median for the overall population.

Results We identified 719 exacerbations between 1/4/2013- 31/3/2014. The number of exacerbations ranged from 157–228/quarter with the winter quarters (Q3/4) being associated with the highest exacerbation frequency. Exacerbators had a median (IQR) age of 46 (31–64) years, length of stay of 2 (1–5) days, Charlson score 4[4–4]. The majority of patients were female (72%). The percentage of repeat attender was 12% of the total population with the highest percentage in the winter quarters. Logistic regression models identified that ethnicity (non-white/Caucasian), baseline admission CRP, neutrophil count, age, coding of status asthmaticus and Charlson co morbidity index significantly increased length of stay beyond the median of 2 days. In contrast neither admission or highest ever blood eosinophil count influenced the median length of stay.

Conclusions We have identified a number of factors associated with an increased length of stay in asthma hospital exacerbations in Leicester. Our observations support the notion that age, comorbidity and biochemical features of infection rather than eosinophilic inflammation increase length of stay. Further research is required to examine the mechanisms that underpin asthma admissions in this population and to reduce length of stay.

COPD phenotyping

| P58 | A COMPARISON BETWEEN THE CLINICAL FEATURES OF PISZ AND PIZZ PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY |

[1]S Vayalapra, [2]RG Edgar, [2]D Griffiths, [2]RA Stockley, [1]AM Turner. [1]University of Birmingham, Birmingham, UK; [2]University Hospitals Birmingham NHSFT, Birmingham, UK

Introduction Alpha-1 antitrypsin deficiency (AATD) is a hereditary disorder affecting about 1 in 3000 people in the UK commonly associated with early-onset emphysema. There are two common deficiency alleles - PiS and PiZ. PiZZ patients have severe AATD, with levels of 10–15% normal. PiSZ patients have less severe deficiency (≈ 40% normal) and are generally thought to have a minimal risk. We hypothesised that if PiSZ patients were at lower risk of COPD than PiZZ, and their lung disease would be more characteristic of usual COPD than that of PiZZ patients.

Method 104 PiSZ patients and 638 PiZZ patients from the UK AATD registry (ADAPT) were compared for their demographics, lung function, risk factors for COPD (e.g. smoking, occupation), co-morbidities associated with COPD, index status (i.e. if diagnosed due to lung disease or family screening) and CT densitometry (where available). Outcome in terms of lung function decline and mortality was also assessed. Univariate statistics were used to guide subsequent regression analyses.

Results Emphysema was more likely in PiZZ than PiSZ patients (OR 11.0 (5.7–21.3); p < 0.001) in the regression analysis after accounting for age, pack years and lung index status. PiZZ patients also had significantly worse FEV1 and DLCO than PiSZ patients in similar regression models (both p < 0.01). Emphysema was more severe in both upper and lower zone (both p < 0.01), and proportionately greater in the lower zone (UZ/LZ VI

= 1.5 v 1.2) in PiZZ patients. Mortality and DLCO decline were also greater in PiZZ patients.

Conclusion PiSZ patients have a milder form of AATD associated with better lung function. The data suggests the pattern of emphysema is closer to usual COPD than classical AATD. Further analyses comparing PiSZ to PiMM are now ongoing.

| P59 | UTILITY OF FIB4 SCORE AND LIVER DISEASE IN ALPHA-1 ANTITRYPSIN DEFICIENCY (A1ATD) |

[1]D Bruce-Hickman, [1]AD Saleh, [1]B Gooptu, [1]DA Lomas, [2]D Thorburn, [1]JR Hurst. [1]The London Alpha-1 Antitrypsin Deficiency Service, UCL Respiratory, London, UK; [2]Department of Hepatology, Royal Free London NHS Foundation Trust, London, UK

Introduction A1ATD is an autosomal co-dominant condition where homozygosity for the Z-allele results, classically, in emphysematous lung involvement, and liver fibrosis dependant on polymerisation rate of aberrant protein.[1] The FIB4 score non-invasively estimates risk of liver fibrosis,[2] but has not previously been investigated in A1ATD. We completed preliminary assessment of the utility of FIB4 in our A1ATD cohort. Whilst the standard of care in A1ATD should be joint respiratory-hepatology services, not all patients are able to access this. A simple tool to guide referral to hepatology services could therefore be clinically useful to the respiratory community.

Methods We report data from 30 PiZZ patients with ultrasound (USS) characterisation of liver disease. An abnormal USS was considered as any abnormality other than cysts, thus including features of cirrhosis and fatty infiltration. FIB4 was calculated as [Age (years)xAST(U/l)]/[Platelets (10^9)xALT(U/l)]. The most recent lung physiology was recorded as FEV1 (%predicted), diffusion coefficient (KCO,%predicted) and residual volume (RV,%predicted). Body mass index (BMI) was calculated.

Results The 30 patients had a mean age of 54 ± 12.4 years, 14 were male. Lung function showed mean FEV1 1.85 ± 1.12 L

Abstract P59 Figure 1 ROC of the FIB4 index for detection of abnormal USS